Agenda

Date and TimeTitle
Mar 2, 2021
10:00am - 10:45am (Eastern)
Keynote – Moving Pharmacogenomics from Portrait to Landscape

Pharmacogenomics has had rapid implementation over the past decade, with recent growth in application in oncology, mental health, solid organ transplantation, and more.  With the application of panel testing, there are often additional opportunities to impact a patient’s care, beyond the specific disease focus area.

Mar 2, 2021
10:50am - 11:45am (Eastern)
Preparing Policy: Citizen Petition for Pre-treatment DPD Testing in Patients Receiving Fluorouracil or Capecitabine Chemotherapy

Fluorouracil and capecitabine are widely used in the chemotherapy treatment of patients with several forms of solid tumor cancer, including gastrointestinal, head/neck and breast cancer. Dihydropyrimidine Dehydrogenase (DPD) deficiency, whether partial or complete, puts patients at risk of severe toxicity or even death when treated with FDA approved doses of fluorouracil or capecitabine. During this session, speakers will discuss progress toward universal pre-treatment DPD testing in patients receiving fluoropyrimidine chemotherapy including a citizens petition to revise the package inserts for Fluorouracil and capecitabine to recommend pre-treatment testing to identify patients with DPD Deficiency and prevent toxicity.

Mar 2, 2021
11:50am - 12:40pm (Eastern)
Incorporating PGx into Clinical Practice

Incorporating PGx into Clinical Practice

Mar 2, 2021
12:45pm - 1:20pm (Eastern)
Fireside Chat

Fireside Chat

Mar 2, 2021
1:25pm - 2:20pm (Eastern)
Moving from Precise to Personalized: Comprehensive Medication Management with Pharmacogenomics in Practice

Optimizing medication use through comprehensive medication management (CMM) in practice moves us to care that is precise and personalized. Pharmacogenomics (PGx) testing makes treatment more precise. Using PGx as a tool within the CMM process makes care personalized. Integrating the two ensures we get medications right at scale, leading to better health and lower costs across populations. But, how do we do this?

To find out, join our panel discussion with Anthony Morreale, Pharm.D., associate chief consultant for clinical pharmacy services and policy at the U.S. Dept. of Veterans Affairs, and Jane Cheshire-Gilbert, CPA, director of retiree health care for the Teachers’ Retirement System of Kentucky, moderated by Katherine H. Capps, co-founder and executive director of the GTMRx Institute.

Anthony will discuss the integration of CMM within the VA while Jane will present the benefits of CMM with PGx for retirees from the health plan administrator point of view.

Mar 2, 2021
2:25pm - 3:05pm (Eastern)
Overcoming the Challenges of Community Care Adoption of PGx

Whilst the Pharmacogenetic (PGx) & Clopidogrel lawsuit and recent award to Hawaii, will help in ‘adoption out of fear’, the underlying challenges of PGx use in community care remain. We will look at some of the significant advances to remove these barriers and enable seamless PGx use in the care-workflow. This informative session is not one to miss.